- Home
- PAYO vs DNLI Comparison
PAYO vs DNLI Comparison
Compare PAYO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- DNLI
- Stock Information
- Founded
- PAYO 2005
- DNLI 2013
- Country
- PAYO United States
- DNLI United States
- Employees
- PAYO N/A
- DNLI N/A
- Industry
- PAYO EDP Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYO Technology
- DNLI Health Care
- Exchange
- PAYO Nasdaq
- DNLI Nasdaq
- Market Cap
- PAYO 2.2B
- DNLI 1.9B
- IPO Year
- PAYO N/A
- DNLI 2017
- Fundamental
- Price
- PAYO $6.78
- DNLI $13.96
- Analyst Decision
- PAYO Strong Buy
- DNLI Strong Buy
- Analyst Count
- PAYO 8
- DNLI 15
- Target Price
- PAYO $10.44
- DNLI $33.85
- AVG Volume (30 Days)
- PAYO 4.3M
- DNLI 1.3M
- Earning Date
- PAYO 05-07-2025
- DNLI 07-31-2025
- Dividend Yield
- PAYO N/A
- DNLI N/A
- EPS Growth
- PAYO N/A
- DNLI N/A
- EPS
- PAYO 0.28
- DNLI N/A
- Revenue
- PAYO $996,150,000.00
- DNLI N/A
- Revenue This Year
- PAYO $4.12
- DNLI N/A
- Revenue Next Year
- PAYO $4.91
- DNLI $256.73
- P/E Ratio
- PAYO $24.18
- DNLI N/A
- Revenue Growth
- PAYO 14.86
- DNLI N/A
- 52 Week Low
- PAYO $5.03
- DNLI $10.57
- 52 Week High
- PAYO $11.29
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- PAYO 45.81
- DNLI 49.11
- Support Level
- PAYO $6.77
- DNLI $12.86
- Resistance Level
- PAYO $6.94
- DNLI $13.77
- Average True Range (ATR)
- PAYO 0.19
- DNLI 0.77
- MACD
- PAYO -0.02
- DNLI -0.04
- Stochastic Oscillator
- PAYO 12.37
- DNLI 57.29
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.